# Assessing the Catalytic Role of Native Glucagon Amyloid Fibrils

Ashim Nandi,<sup>1,+</sup> Aoxuan Zhang,<sup>1,+</sup> Elad Arad,<sup>2,3,4</sup> Raz Jelinek<sup>2,3</sup> and Arieh Warshel<sup>1,\*</sup>

<sup>1</sup>Department of Chemistry, University of Southern California, Los Angeles, California 90089-1062, United States. \*Email: <u>warshel@usc.edu</u>

<sup>2</sup>Ilse Katz Institute (IKI) for Nanoscale Science and Technology, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.

<sup>3</sup>Department of Chemistry, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.

<sup>4</sup>Department of Chemical Engineering, Columbia University, New York, NY 10027, United States.

<sup>+</sup> Co-first authors

KEYWORDS: Amyloid Fibrils, Catalysis, Kinetics, Peptides and Proteins, Mechanisms, Binding Energy.

#### Abstract

Glucagon stands out as a pivotal peptide hormone, instrumental in controlling blood glucose levels and lipid metabolism. While the formation of glucagon amyloid fibrils has been documented, their biological functions remain enigmatic. Recently, we demonstrated experimentally that glucagon amyloid fibrils can act as catalysts in several biological reactions, including esterolysis, lipid hydrolysis, and dephosphorylation. Herein we present a multiscale quantum mechanics/molecular mechanics (QM/MM) simulation of the acylation step in the esterolysis of *para*-nitrophenyl acetate (*p*-NPA), catalyzed by native glucagon amyloid fibrils, serving as a model system to elucidate their catalytic function. This step entails a concerted mechanism, involving proton transfer from serine to histidine, followed by the nucleophilic attack of serine oxy anion on the carbonyl carbon of p-NPA. We computed the binding energy and free-energy profiles of this reaction using the PDLD/S-LRA-2000 and the empirical valence bond (EVB) methods. This included simulations if the reaction in an aqueous environment and in the fibril, enabling us to estimate the catalytic effect of the fibril. Our calculations obtained a barrier of 23.4 kcal·mol<sup>-1</sup> for the enzyme-catalyzed reaction, compared to the experimental value of 21.9 kcal·mol<sup>-1</sup> (and a calculated catalytic effect of 3.2 kcal·mol<sup>-1</sup> compared to the observed effect of 4.7 kcal mol<sup>-1</sup>) This close agreement together with the barrier reduction when transitioning from the reference solution reaction to the amyloid fibril provides supporting evidence to the catalytic role of glucagon amyloid fibrils. Moreover, by employing the PDLD/S-LRA-2000 approach further reinforced exclusively the enzyme's catalytic role.

The results presented in this study contribute significantly to our understanding of the catalytic role of glucagon amyloid fibrils, marking, to the best of our knowledge, the first principle mechanistic investigation of fibrils using QM/MM methods. Therefore, our findings offer fruitful insights for future research on the mechanisms of related amyloid catalysis.

## Introduction

Amyloids, initially identified as anomalous sugar deposits in various tissues, including diseased brains, were subsequently revealed to be protein-based structures.<sup>1</sup> Its specific structural characteristics were long shrouded in mystery until early X-ray diffraction studies on aggregated globulins provided hints of a distinctive design having intermolecular beta sheets oriented perpendicularly to the strand direction, forming the characteristic cross- $\beta$  pattern seen in most amyloid structures.<sup>1–3</sup> While amyloids have often been linked to various human diseases such as Alzheimer's and Parkinson's,<sup>4,5</sup> it has become apparent that not only disease-related proteins adopt this structure. Surprisingly, many proteins can transition into the amyloid state under certain conditions, occasionally leading to new health-related issues.<sup>6–9</sup> Recent advances have further expanded our understanding, revealing that numerous human proteins, even those unrelated to pathological conditions, can adopt a fibrillar amyloid-like organization, both in laboratory settings (*in vitro*) and within living organisms (*in vivo*).<sup>10–13</sup>

Among these proteins is glucagon, a peptide hormone composed of 29 amino acid residues in conjunction with insulin helps in regulating blood glucose level.<sup>14,15</sup> This hormone is present in a wide variety of animals and is primarily synthesized in the pancreas, specifically by  $\alpha$  cells.<sup>16,17</sup> It hold a significant role in various metabolic pathways, influencing lipid metabolism, energy regulation, and amino acid metabolism.<sup>15,18,19</sup> Irregularities in glucagon levels can contribute to various pathological conditions, including insulin resistance (linked to type-2 diabetes) and glucagonoma, which involves an elevated turnover of amino acids in the liver and irregular triglyceride breakdown.<sup>20–22</sup>

Though the exact biological functions of these glucagon fibrils have largely remained unexplored, it was suggested that amyloid fibrils as a group played a role in primitive catalytic reactions.<sup>23,24</sup> This phenomenon was first demonstrated in synthetic amyloid-like systems.<sup>25,26</sup> Recent experimental work has unveiled a catalytic potential of amyloid fibers formed by peptides like Alzheimer's disease peptide amyloid- $\beta$  (A $\beta$ )<sup>27</sup> and glucagon,<sup>28</sup> particularly when they take on a fibrillar form, unlike their monomeric counterparts. This finding suggests that the polymeric structure of amyloid fibers offers unique catalytic sites on their surface.<sup>29</sup> Additionally, another independent research team has established that amyloid fibers formed by  $\alpha$ -synuclein also exhibit enzyme-like catalytic properties in biological reactions.<sup>30</sup> Collectively, these findings have indicated that naturally occurring amyloids can catalyze a range of physiological and pathological reactions, distinguishing them from synthetic, pre-designed amyloidogenic peptides. Given this emerging understanding, it encouraged us to delve into an atomistic examination of the catalytic mechanisms at play within the glucagon amyloid fibrils using QM/MM approaches.

Estimation of the structure-function activity of amyloids originated from natural sequences is a challenging task: Unlike other highly ordered proteinaceous systems, the amyloid state is a misfolded state.<sup>4</sup> Moreover, polymorphism is a key feature of amyloid fibrillar structures, due to their assembly process and surrounding conditions.<sup>31–33</sup> Glucagon, in particular, was shown to form several polymorphs, depending on the local microenvironment at the early stages of the protofibril assembly,<sup>10,34</sup> reflecting that the fibrils do not reach singular global energy minimum.<sup>35,36</sup> Yet, all polymorphs consist of common features such as  $\beta$ -sheet assembly in which the strands are spread and oriented in juxtaposed to each other in antiparallel fashion.<sup>34</sup> In respect to polymorphism, although may slightly differ at the mature fibrillar level, the cross- $\beta$  fashion remains dominant.

In the realm of enzyme catalysis, the hallmark is the accelerated pace of enzymatic reactions compared to their counterparts in reference aqueous solutions. To comprehensively assess the catalytic influence of the enzyme environment, it is essential to consider the corresponding reaction in a reference solution. The Empirical Valence Bond (EVB) approach,<sup>37–39</sup> as outlined in section 2.2, stands as a favored computational

method in enzymology. Its appeal lies in its computational efficiency and its ability to seamlessly incorporate parameters relevant to the reference reaction.

This paper aims to shed light on the catalytic mechanism governing the esterolysis of *para*-nitrophenol acetate (*p*-NPA) by human glucagon fibrils,<sup>28</sup> using it as an illustrative model of catalysis, with a specific focus on the acylation step involving proton transfer and nucleophilic attack (PT-NA). Our investigation employs PDLD/S-LRA-2000 method,<sup>40</sup> detailed in section 2.1, for extensive binding energy calculations and qualitative assessments of catalytic activity in the studied system. We employed the EVB method for rigorous elucidation of the reaction mechanism. For calibration of the EVB treatment, it is imperative to evaluate the thermodynamic and kinetic parameters of the reference reaction.<sup>41</sup> In this study, we derived the EVB parameters of the reference reaction in water through a combination of experimental and ab-initio data, as previously reported in our works.<sup>41</sup> By combining these computational approaches, our work offers a deeper understanding of the catalytic mechanisms at play within glucagon amyloid fibrils.



**Scheme 1.** Docked structure of the substrate *para*-nitrophenol acetate (*p*-NPA) in NMRdetermined-structure of glucagon amyloid fibril (PDB entry: 6NZN)<sup>13</sup> (left), and schematic reaction showing concerted Proton Transfer–Nucleophilic Attack (acylation step) in the esterolysis of *p*-NPA (right). In the EVB representation, the reactant is described by the state 1 and the product by state 2.

### 2. Computational Methods

The catalytic effects were studied using the empirical valence bond (EVB) method. The corresponding activation free energies were calculated by the free energy perturbation/umbrella sampling (FEP/US).<sup>42</sup> The EVB and FEP/US approaches, previously detailed and utilized in numerous prior studies,<sup>37,38</sup> are concisely reviewed in the Supporting Information and, partially, below. Additionally, for a thorough examination of the binding energy calculations, and a qualitative evaluation of the catalytic effect, we also employed the PDLD/S-LRA-2000 method, which is succinctly described in the following sections.

The structure of the studied enzyme was sourced from the Protein Data Bank, specifically utilizing the crystal structure found under PDB entry 6NZN.<sup>13</sup> The substrate employed in the present study was *para*-nitrophenyl acetate (*p*-NPA), which was optimized using the M06-2X/Def2-TZVP level of theory in the Gaussian16 software suite.<sup>43</sup> Following this, the optimized structure was docked into the enzyme using AutoDock software.<sup>44</sup> A variety of docked structures were evaluated as discussed below. The atomic charges of the QM region were determined from Electrostatic Potential (ESP)<sup>45</sup> charges, computed by Gaussian16 at the M06-2X/Def2-TZVP level with the inclusion of the SMD solvation model.<sup>46</sup> These resultant charges were utilized to generate the restrained electrostatic potential (RESP)-fitted charges<sup>47</sup> via AmberTools.<sup>48</sup> The RESP charges were exclusively applied to the substrate and the reacting residues, Serine and Histidine, whereas the ENZYMIX force field<sup>49</sup> was utilized for the atoms of the enzyme and water. All the calculations were carried out using the MOLARIS-XG package.<sup>49</sup>

# 2.1. The Empirical Valence Bond (EVB) Method

The reliability of the Empirical Valence Bond (EVB) method hinges on conducting enzyme calculations relative to the same reaction taking place in a water environment, as mentioned earlier. The energetics of the reference reaction in water is based on a combination of experimental information and ab-initio data, which was detailed in our

previous work<sup>41</sup> and depicted in Figure S1. To create the reference system, we employed a Surface Constraint All Atom Solvent (SCAAS)<sup>50</sup> sphere with a radius of 20 Å to solvate the system. This surface-constrained water sphere was encompassed by a 10 Å surface layer composed of Langevin dipoles,<sup>51,52</sup> followed by the bulk solvent. Long-range electrostatic effects were treated using the local reaction field (LRF) method.<sup>53</sup> The system underwent relaxation in seven sequential steps, commencing at a temperature of 5 K. Subsequently, the temperature was gradually increased up to the experimental temperature of 310 K, over an overall relaxation time of 200 ps, resulting in the generation of five distinct starting structures. For the reference system, mirroring the reacting system in water, we adhered to the same protocol as employed in the enzyme calculations. The determination of reaction free energy profiles was carried out using the EVB method, wherein, in the case of two resonance states, the ground state energy (*E<sub>g</sub>*) was computed through the solution of the secular equation given by,

$$\begin{vmatrix} H_{11} - E_g & H_{12} \\ H_{21} & H_{22} - E_g \end{vmatrix}$$

Here,  $H_{11}$  and  $H_{22}$  represent the diabatic energies of the reactant and product states. Throughout the simulation, the reaction progresses using a free energy perturbation (FEP) technique, which alters the system's potential (*V*) by transitioning from the reactant state to the product state through a coupling parameter ( $\lambda$ ) given by,

$$V(\lambda) = \lambda \cdot H_{11} + (1 - \lambda) \cdot H_{22} \tag{1}$$

The collected data is subsequently employed in a specialized umbrella sampling approach<sup>54</sup> to construct the actual free energy profile of the reaction.

In this study, each simulation was conducted in five different replicas. Each replica underwent an FEP simulation consisting of 31 frames, where the coupling parameter  $\lambda$  was incrementally changed in 31 equal steps of 0.03. Each MD frame involved a 20 ps equilibration under the potential  $V(\lambda)$ . The five replicas began from distinct initial configurations obtained through five successive 20 ps equilibration steps. For the reference reaction in water, the serine and histidine residues were C $\alpha$ -methylated. During

the MD simulations, a force of 10 kcal/mol/Å<sup>2</sup> was applied to keep the C $\alpha$  atoms in their original positions. Otherwise, the FEP protocol in water mirrored that in the enzyme.

The EVB simulations for the reference solution reaction were calibrated by adjusting the gas phase shift and the off-diagonal coupling to match the reaction profile presented in Fig S1. After calibrating the EVB parameters, they remained unchanged for simulating the reaction in the enzyme. In these simulations, the full atomistic effects of the entire enzyme were considered, except for atoms outside the solvation sphere, which were constrained by 10 kcal/mol/Å<sup>2</sup> to their original positions. Consequently, due to these constraints, some degrees of freedom contributing to the reaction entropy were not considered. The EVB parameters, including the RESP charges, are provided in the Supporting Information.

### 2.2. The Semi-macroscopic protein dipole-Langevin dipole (PDLD/S) method

Besides utilizing the EVB method, the enzyme's catalytic effect can also be estimated using a modified semi-macroscopic version of the Protein–Dipole Langevin–Dipole (PDLD) method within the Linear Response Approximation (LRA) framework, termed PDLD/S-LRA-2000.<sup>40,55,56</sup> This approach similar to our original PDLD/S-LRA method involves scaling the non-electrostatic term (C) (see below). In this method, the protein is considered a medium with a "dielectric constant" ( $\varepsilon_{im}$ ), signifying all implicitly treated contributions and involving thermodynamic cycles by adjusting the solvent's (water) dielectric constant ( $\varepsilon_w$ ) from its actual value  $\varepsilon_w$  to  $\varepsilon_{im}$ . Within the Linear Response Approximation (LRA) framework,<sup>57</sup> the PDLD/S free energies accommodate the effect of protein and solvent reorganization throughout the binding cycle, detailed in our previous works.<sup>57,58</sup> In our current work, the binding free energy is expressed as:

$$\Delta G_{bind}^{PDLD/S-LRA-2000} \cong \alpha \Delta G_{bind}^{elec} + Cx \Delta G_{bind}^{non-elec}$$

$$\cong \frac{1}{2} \left[ \left( \langle U_{\text{elec},I}^{\text{p}} \rangle_{\text{Q}=\text{Q}_{0}} + \langle U_{\text{elec},I}^{\text{p}} \rangle_{\text{Q}=0} \right) - \left( \langle U_{\text{elec},I}^{\text{w}} \rangle_{\text{Q}=\text{Q}_{0}} + \langle U_{\text{elec},I}^{\text{w}} \rangle_{\text{Q}=0} \right) \right] + Cx\Delta G_{\text{bind}}^{\text{non-elec}}$$
(2)

In which superscript 'p' and 'w' refer to protein and water environments, respectively. 'Q' represents the substrate atoms' charge distribution, which alternates between its actual

charge distribution and zero throughout the binding cycle (see ref. 40 and 55). The  $\langle \rangle_q$  notation indicates an average over configurations from MD simulations with the specified Q. The non-electrostatic term accounts for binding free energy from hydrophobic effects, van der Waals, water penetration and entropy contribution.

The scaling factor C for the non-electrostatic contribution, critical in our analysis, was treated with care following our 2000 benchmark study.<sup>56</sup> This C factor is not a universal constant but is specific to the studied system, influenced by a complex balance of thermodynamic contributions like van der Waals interactions, hydrophobic effects, water penetration, and configurational entropy changes, further explained in ref.<sup>56</sup> For the current study, we determined an optimal C value of 0.70, which effectively calibrates calculated binding affinity with experimental observation (*vide infra*).

The electrostatic contributions are obtained by the effective PDLD/S-LRA potentials:

$$\overline{U}_{elec,l}^{p} = \left[ \left( \Delta G_{sol}^{l+p} - \Delta G_{sol}^{l'+p} \right) \left( \frac{1}{\varepsilon_{in}} - \frac{1}{\varepsilon_{w}} \right) + \Delta G_{sol}^{l} \left( 1 - \frac{1}{\varepsilon_{w}} \right) + \frac{U_{q\mu}^{l}}{\varepsilon_{in}} + \frac{U_{intra}^{l}}{\varepsilon_{in}} \right]_{B}$$
(3)

$$\overline{U}_{elec,I}^{w} = [\Delta G_{sol}^{I}(1 - \frac{1}{\varepsilon_{w}}) + \frac{U_{intra}^{I}}{\varepsilon_{in}}]_{UB}$$
(4)

In the above expression, the solvation free energy,  $\Delta G_{sol}^{solute}$ , of a system is assessed by the microscopic (unscaled) PDLD method. The superscripts of the solvation energy, 'l+p' and 'l'+p', refer to ligand-protein complex in their charged states and the same complex with a non-polar ligand (i.e., all atomic charges of the ligand are assigned to zero). The parameter, not directly tied to the actual protein "dielectric constant", accounts for implicitly treated contributions.<sup>48,49</sup> Typically, when protein reorganization energy is explicitly considered, it is reasonable to use.<sup>49,50</sup> U<sup>I</sup><sub>qµ</sub> reflects the vacuum interaction between ligand charges and protein dipoles. U<sup>I</sup><sub>intra</sub> is the intramolecular electrostatic interaction of the ligand. The subscripts 'B' and 'UB' refer to the sampling of the configurations in protein (bound, B) and in water (unbound, UB) respectively. And non-electrostatic contributions are estimated by:

$$\Delta G_{\text{bind}}^{\text{non-elec}} = \Delta G_{\text{bind}}^{\text{hyd}} + \Delta G_{\text{bind}}^{\text{vdw}}$$
(5)

 $\Delta G_{bind}^{hyd}$  represents a field-dependent hydrophobic term, estimating relevant surface area considering the local field on each Langevin dipole in the initial "solvation shell."  $\Delta G_{bind}^{vdw}$  pertains to the van der Waals contribution.

Finally, calculating the catalytic effect entails assessing the binding energy in both the ground and transition states by employing,

$$(\Delta \Delta g^{\ddagger})^{w \to p} = (\Delta G^{\ddagger}_{bind} - \Delta G^{\circ}_{bind})^{w \to p}$$
(6)

where  $\Delta G_{bind}^{\dagger}$  and  $\Delta G_{bind}^{\circ}$  represent the binding energy of the transition and ground state, respectively. The mean of equation 2 for both states is derived using a central force field, wherein the minimum energy structure aligns with that of the corresponding EVB surface. The relevant charges from the central force field are adapted from the corresponding EVB charges.

The substrate binding free energy was calculated by the Protein Dipoles Langevin Dipoles method in its linear response approximation (PDLD/S-LRA)-using a sampling of 4 different configurations collected at every 10 ps of successive MD relaxation. In these calculations, we used a dielectric constant of 4, whose effect accounts for the poor configurational sampling and lack of nuclear and electronic polarization effects.<sup>59,60</sup>

To ensure the reproducibility of our results, we have included both our docked structures, parameters, and the complete input files in the Supporting Information. Additionally, a GitHub link to access these materials is provided therein.

### 3. Results and Discussion

A comparative scrutiny of various glucagon variants in our prior experimental study facilitated the localization of the catalytic activity to an enzyme-like pocket formed on the surface of the glucagon fibril, which includes the histidyl-serine domain at the peptide's N-terminus. Based on this knowledge, we carried out extensive docking and binding energy calculation of the different poses of the substrate *p*-NPA bound around this catalytic-dyad. This was followed by investigating into the catalytic mechanism using the EVB and PDLD/S-LRA-2000 methods.

## 3.1 Binding Energy

The binding mode of *p*-NPA within the fibril has not yet been determined experimentally. To address this, we utilized an NMR-determined crystal structure (PDB entry: 6NZN), with ten submitted conformers) as a template to search for potential binding modes. Since the catalytic residues are exclusively located at the peptide termini as mentioned above, we conducted an automatic docking targeting the termini of the fibril across all ten conformers. These docked structures were then manually adjusted to produce suitable starting points for subsequent binding and reaction energy profile calculations. Notably, we explored several configurations of our substrate and binding poses during the docking process, namely, the Re and Si faces of the carbonyl carbon of p-NPA binding in the outer surface, same chain, same layer, and different layer on the amyloid fibril (see Fig. 1). To further validate our findings, we employed the PDLD/S-LRA-2000 method to determine the binding energy for each docking mode. For each mode, we conducted five distinct simulations, each initialized with different structures sampled by the ENZYMIX force field. The results presented are averages from these simulations. During every PDLD/S-LRA simulation, the linear response approximation (LRA) calculation was executed on ten different configurations sampled throughout the trajectory.



**Figure 1.** Docked structures showcasing various poses of the substrate *p*-NPA: (a) Positioned on the different layer with the carbonyl carbon facing the *Re*-side of the NA attack (*Re*), (b) Located on a different layer with the carbonyl carbon facing the *Si*-side, (c) On a same layer with the carbonyl carbon oriented towards the *Re*-side, (d) on the same layer with the carbonyl carbon facing the *Si*-side, (e) On the same chain with the carbonyl carbon facing the *Re*-side, (f) On the same chain with the carbonyl carbon oriented towards the *Si*-side. Note: The residue numbering in the hundreds is attributed to the presence of 10 conformers in the PDB NMR structures. The structures shown here are selected for their relevance in kinetic and binding studies.

The binding energies for the various poses are presented in Table 1. It is evident that the binding energies across different configurations are relatively similar, with notable exceptions being the surface, different layer (*Re*), and same layer (*Re*) poses. These values are in close alignment with the experimentally observed binding energy. This suggests the possibility of multiple binding sites. However, it also highlights the challenge of identifying the optimal binding pose due to the extremely flat surface of the fibril and the lack of distinct catalytic pockets. Nevertheless, the binding energies are in excellent

agreement with the observed value of -3.34 kcal·mol<sup>-1</sup>, particularly for the poses with different layer (*Si*), the same chain (*Re*), and the same layer (*Si*), which have binding energies of -3.23, -3.40, and -3.42 kcal·mol<sup>-1</sup>, respectively (refer to Fig. 1b, e, and f). For the downstream EVB free energy calculations, the same chain (*Re*) pose was selected due to the proper orientations of the catalytic residues, Ser118 and His117, facilitating the PT-NA process (see Fig. 1e). This is in contrast to other potential poses, where the proton of Ser147 is oriented away from the N<sub>δ</sub> of His117 (Fig 1b). It is worth noting that we also investigated the reaction mechanism with the same layer (*Si*) pose but found its free energy profile to be kinetically unfavorable with EVB activation barrier of over 25 kcal·mol<sup>-1</sup>.

Poses	∆ <i>G<sub>calc</sub></i> (kcal·mol <sup>-1</sup> )	
Surface	-1.29	
Different layer (Re)	-1.34	
Different layer (Si)	-3.23	
Same layer ( <i>Re</i> )	-1.39	
Same layer (Si)	-3.42	
Same chain ( <i>Re</i> )	-3.40	
Same chain ( <i>Si</i> )	-2.82	
<sup>a</sup> From the experimental $K_m$ measured at pH 7.4, we approximated		
the binding energy using equation $\Delta G_{exp} = -RT ln K_m = -3.34$ .		

 Table 1. The PDLD/S-LRA-2000 Binding Energy Calculations for the Different Poses<sup>a</sup>.

## 3.2 EVB Reaction Mechanism

Our study centers on the acylation step, which involves a concerted proton transfernucleophilic attack (PT-NA), as illustrated in Scheme 1. The calibration of the reference solution draws upon our previously determined experimental free energy profile for the acylation step of esterolysis. It is important to note that the reference solution reaction in our prior study was executed via a stepwise reaction, involving a proton transfer (PT), followed by a nucleophilic attack (NA). While for the current study, we computed the EVB free energy profile for this stepwise mechanism, the intermediate formed post-PT was found to have an ascending free energy curve lacking minima suggesting a fleeting intermediate formation. Consequently, we shifted our attention to exploring the concerted PT-NA, hypothesizing it as the possible mechanism and identifying it as the ratedetermining step (RDS). To calibrate the reference solution for the concerted PT-NA, we derived the activation and reaction energy from the overall free energy profile of the stepwise mechanism, based on our previous study.<sup>41</sup> This study assumed that the RDS remains consistent across both mechanisms. The reference profile can be found in the Supporting Information.

The EVB reaction profiles for the reference reaction in water and in glucagon fibril enzyme are shown in Figure 2. The energetics for the concerted PT-NA reference reaction in water was obtained using a distance constraint of 10 kcal/mol/Å<sup>2</sup> at 3.5 Å between the O and N<sub> $\delta$ </sub> atoms of Ser118 and His117 for the PT, and between the O of Ser118 and the carbonyl carbon atom of the ester group for the NA. In contrast, within the fibril, we applied a 2 kcal/mol/Å<sup>2</sup> distance constraint for the same atom pairs.



**Figure 2.** Free Energy Profiles for the Concerted Proton Transfer–Nucleophilic Attack (acylation step) in the esterolysis of *para*-Nitrophenyl Acetate (*p*-NPA). The reference profile in solution is represented in black, while the amyloid fibril-catalyzed profile is illustrated in blue. The reaction

coordinate is defined by the energy difference between EVB states 2 and 1, a measure typically used to display EVB free-energy profiles (see derivation in the Supporting Information).

The computed EVB free energy barrier for the PT-NA (acylation step) reaction is 23.4 kcal mol<sup>-1</sup>, aligning closely with the experimental value of 21.9 kcal·mol<sup>-1</sup>. The reaction free energy for the enzyme-catalyzed reaction is exergonic, registering at -1.7 kcal·mol<sup>-1</sup>. Both the experimental and calculated kinetic parameters for the enzyme-catalyzed reaction are listed in Table 2.

# Table 2. Experimental and Calculated Kinetic Parameters, Alongside Calculated Reaction Free Energy for the Glucagon Fibril Catalyzed Esterolysis of *p*-NPA<sup>a</sup>.

$k_{exp}^{cat}(\mathbf{s}^{-1})$	∆ <i>G</i> <sup>‡</sup> <sub>exp</sub> (kcal⋅mol <sup>-1</sup> )	∆ <i>G</i> <sup>‡</sup> <sub>calc</sub> (kcal·mol <sup>-1</sup> )	∆ <i>G<sub>calc</sub></i> (kcal·mol <sup>-1</sup> )
2.5 × 10 <sup>-3</sup>	21.9	23.4	-1.7

<sup>a</sup>Experimental free energy barrier  $\Delta G_{exp}^{\ddagger}$  was derived from the experimental rate constant,  $k_{exp}^{cat}$  measured at pH 7.4, utilizing the Eyring–Polanyi equation.

In a water environment, the reaction barrier for the acylation step, as determined from experimental and ab-initio calculations in our previous study (and used in the current study for calibration), was found to be 26.6 kcal·mol<sup>-1</sup>. The reaction free energy for the reaction in water is 16.9 kcal·mol<sup>-1</sup>. Notably, this value is destabilized by 18.6 kcal·mol<sup>-1</sup> compared to that for the glucagon fibril active site, suggesting that the charged intermediates following the PT-NA are highly stabilized, and the reaction becomes exothermic within the enzyme, whereas it is highly endothermic in the water environment. A comparison of the activation free energies between the reference solution and enzymatic environments reveals that the glucagon fibril lowers the barrier by 3.2 kcal·mol<sup>-1</sup> relative to water. By employing the transition-state theory, the corresponding increase in the reaction rate constant can thus be estimated to be about two orders of magnitude  $(\mathbf{k}_{calc}^{cat} \sim 2 \times 10^{-04} \text{ s}^{-1})$  at the experimental temperature. This implies that the reaction in the aqueous solution, which is extremely slow  $(\mathbf{k}_{calc}^{wat} \sim 1.1 \times 10^{-06} \text{ s}^{-1})$  under normal experimental

setup. This strongly provides atomistic evidence of the catalytic effect of glucagon fibril in the esterolysis of *p*-NPA, in agreement with our previous experimental study.

### 3.3 PDLD/S-LRA-2000 Calculations

To further validate our findings, we also assessed the activation energy using the PDLD/S-LRA-2000 method, as outlined in Section 2.2. The binding energies for the ground and transition states were determined by employing the substrate and a pertinent fragment of the catalytic dyad (illustrated in Scheme 1), with charges derived from charge set of the diabetic state 1. The binding energy calculations involved generating relaxed structures through MD simulations, conducted under the conditions summarized in Table 3. Although this study was not as extensive as the EVB study, its primary aim was to evaluate the electrostatic energies in configurations proximal to the NMR structure. Our calculations indicate a reduction in  $\Delta\Delta g^{\ddagger}$  when transitioning from a water to an enzyme environment, yielding a value of -3.9 kcal·mol<sup>-1</sup> (refer to Table 3). This very closely replicates the EVB activation barrier and further substantiates the evidence of catalytic contribution of glucagon fibril.

## Table 3. The PDLD/S-LRA-2000 Activation Energy for the Acylation Step<sup>a</sup>

∆G <sup>°</sup> <sub>bind</sub> (kcal·mol <sup>-1</sup> )	∆ <i>G</i> <sup>‡</sup> <sub>bind</sub> (kcal⋅mol <sup>-1</sup> )	$(\Delta\Delta g^{\ddagger})^{w ightarrow p}$ (kcal·mol <sup>-1</sup> )
-4.2	-8.2	-3.9

<sup>a</sup>The value of  $(\Delta\Delta g^{\ddagger})^{w \to p}$  was derived from Equation 6, evaluating the pertinent  $\Delta G^{\ddagger}_{bind}$  and  $\Delta G^{\circ}_{bind}$  by averaging the corresponding  $\Delta\Delta G_{bind}$  across 4 configurations. Each of these was taken after 20 ps of MD simulation, using  $\varepsilon_p = 4$  and charge set of the diabetic state 1. Initial configurations were produced by conducting 20 ps simulations, utilizing the reaction coordinates of the EVB surfaces of both the reactant state and the transition state.

## 3.4 Origin of Catalytic Effect of Glucagon Fibril

The EVB/FEP and PDLD/S-LRA-2000 computational methods both systematically reflected the enzymatic effect of glucagon fibril on the acylation step, aligning well with the experimental findings detailed above. This overall catalytic effect is linked to the stabilization of the transition state (TS). Upon examining the TS configuration closely, we observed that the benzene ring of p-NPA is engaged in a  $\pi$ -stacking interaction with His118 and His146 at both the TS and tetrahedral intermediate (TI) stages. More importantly, the carbonyl oxygen of p-NPA forms a hydrogen bond with Ser147 at a distance of 2.3 Å at the TS, while the oxyanion hole created in the TI is further stabilized by Ser147, positioned 2.0 Å away. Notably, the distance facilitating the nucleophilic attack between the oxygen of Ser117 and the carbonyl carbon of *p*-NPA is significantly shorter in the fibril compared to a reference water solution at the TS (2.59 Å vs. 3.36 Å). These interactions become more dominant and persist during the formation of the TI in the enzyme (see Fig. 3 for visual inspection), leading to further stabilization of the intermediate, thereby resulting in exergonicity of the reaction. This underscores the idea that enzymes largely attribute their catalytic effect to preorganized electrostatics.<sup>61</sup> The dominant influence of electrostatics is evident in the reaction we examined. In particular, the reaction leads to the formation of the oxyanion-Ser147 pair. As a result, the reaction profiles are affected by the environment. The preorganized electrostatics within the enzyme provide an additional barrier reduction, which might be vital in physiological contexts.



**Figure 3.** Illustration of the transition state and tetrahedral intermediate structures within a reference water solution (top panel) and a native glucagon amyloid fibril environment (bottom panel), highlighting selected bond distances in Angstroms. The water sphere has been omitted for clarity.

# 4. Conclusions

In summary, our study involved a comprehensive exploration of the acylation step in the *p*-NPA esterolysis process, catalyzed by glucagon amyloid fibrils. By employing the stateof-the-art EVB method and PDLD/S-LRA-2000 approach, we unraveled the intricacies of this reaction mechanism, treating it as an instructive test for the catalytic capabilities of glucagon amyloid fibrils—a topic we had previously investigated through experimental means.

Our computational analysis yielded an EVB free activation energy of 23.4 kcal·mol<sup>-1</sup>, a value consistent with the experimentally determined activation energy of 21.9 kcal·mol<sup>-1</sup>. This alignment serves as evidence affirming the validity of the proposed mechanism governing the amyloid fibril-catalyzed esterolysis of *p*-NPA. Furthermore, through a comparative assessment of activation free energies in enzymatic and water

environments, we estimated the catalytic effect—the reduction in the activation barrier imparted by glucagon amyloid fibrils to be approximately 3.2 and 3.9 kcal·mol<sup>-1</sup> by EVB and PDLD/S-LRA-2000 methods. This finding furnishes atomistic proof substantiating the catalytic role played by amyloid fibrils. The key contributor to this catalytic effect appears to be preorganized electrostatics, specifically the formation of the oxyanion-Ser147 pair during the concerted proton transfer and nucleophilic attack process. Consequently, the reaction profiles exhibit a pronounced dependence on the surrounding environment. In the enzyme environment, the barrier is lowered, enabling the reaction from a thermodynamic standpoint, while the prearranged enzyme electrostatics make a supplementary, and likely crucial, contribution to barrier reduction for physiological relevance.

In summation, given that most studies on catalytic amyloids use the esterolysis of *para*nitrophenyl acetate as a benchmark reaction for measuring catalytic activity, our work offers a deeper insight into the catalytic role of glucagon amyloid fibrils, offering valuable insights with broader implications for catalytic amyloid. We anticipate that this work will facilitate further exploration into the atomic-level mechanisms of related amyloid fibrils.

### Notes

The authors declare no competing financial interest.

## Acknowledgements

A.W. is supported by the National Institute of Health R35 GM122472, the National Science Foundation Grant MCB 2142727.

### **ASSOCIATED CONTENT**

The Supporting Information contains a concise overview of the computational methods, the free energy profile for the reference reaction, the parameters employed, and a link to a GitHub repository with all the input files and PDBs.

## References

(1) Ke, P. C.; Zhou, R.; Serpell, L. C.; Riek, R.; Knowles, T. P. J.; Lashuel, H. A.; Gazit, E.; Hamley, I. W.; Davis, T. P.; Fändrich, M.; Otzen, D. E.; Chapman, M. R.; Dobson, C. M.; Eisenberg, D. S.; Mezzenga, R. Half a Century of Amyloids: Past, Present and Future. *Chem. Soc. Rev.* **2020**, *49* (15), 5473–5509. https://doi.org/10.1039/C9CS00199A.

(2) Riek, R. The Three-Dimensional Structures of Amyloids. *Cold Spring Harb. Perspect. Biol.* **2017**, *9* (2), a023572. https://doi.org/10.1101/cshperspect.a023572.

(3) Greenwald, J.; Riek, R. Biology of Amyloid: Structure, Function, and Regulation. *Structure* 2010, *18*(10), 1244–1260. https://doi.org/10.1016/j.str.2010.08.009.

(4) Chiti, F.; Dobson, C. M. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. *Annu. Rev. Biochem.* **2017**, *86* (1), 27–68. https://doi.org/10.1146/annurev-biochem-061516-045115.

(5) Alam, P.; Siddiqi, K.; Chturvedi, S. K.; Khan, R. H. Protein Aggregation: From Background to Inhibition Strategies. *Int. J. Biol. Macromol.* **2017**, *103*, 208–219. https://doi.org/10.1016/j.ijbiomac.2017.05.048.

(6) Sawaya, M. R.; Hughes, M. P.; Rodriguez, J. A.; Riek, R.; Eisenberg, D. S. The Expanding Amyloid Family: Structure, Stability, Function, and Pathogenesis. *Cell* **2021**, *184* (19), 4857–4873. https://doi.org/10.1016/j.cell.2021.08.013.

(7) Cao, Y.; Adamcik, J.; Diener, M.; Kumita, J. R.; Mezzenga, R. Different Folding States from the Same Protein Sequence Determine Reversible vs Irreversible Amyloid Fate. *J. Am. Chem. Soc.* **2021**, *143* (30), 11473–11481. https://doi.org/10.1021/jacs.1c03392.

(8) Guijarro, J. I.; Sunde, M.; Jones, J. A.; Campbell, I. D.; Dobson, C. M. Amyloid Fibril Formation by an SH3 Domain. *Proc. Natl. Acad. Sci.* **1998**, *95* (8), 4224–4228. https://doi.org/10.1073/pnas.95.8.4224.

(9) Buell, A. K. Stability Matters, Too – the Thermodynamics of Amyloid Fibril Formation. *Chem. Sci.*2022, 13 (35), 10177–10192. https://doi.org/10.1039/D1SC06782F.

(10) *The Nature of Amyloid-like Glucagon Fibrils - Jesper Søndergaard Pedersen, 2010.* https://journals.sagepub.com/doi/abs/10.1177/193229681000400609 (accessed 2023-10-24).

(11) The pro-apoptotic domain of BIM protein forms toxic amyloid fibrils | SpringerLink. https://link.springer.com/article/10.1007/s00018-020-03623-7 (accessed 2023-10-24).

(12) The protofilament structure of insulin amyloid fibrils | PNAS. https://www.pnas.org/doi/abs/10.1073/pnas.142459399 (accessed 2023-10-24).

(13) Gelenter, M. D.; Smith, K. J.; Liao, S.-Y.; Mandala, V. S.; Dregni, A. J.; Lamm, M. S.; Tian, Y.; Xu, W.; Pochan, D. J.; Tucker, T. J.; Su, Y.; Hong, M. The Peptide Hormone Glucagon Forms Amyloid Fibrils with Two Coexisting  $\beta$ -Strand Conformations. *Nat. Struct. Mol. Biol.* **2019**, *26* (7), 592–598. https://doi.org/10.1038/s41594-019-0238-6. (14) Kawamori, D.; Kurpad, A. J.; Hu, J.; Liew, C. W.; Shih, J. L.; Ford, E. L.; Herrera, P. L.; Polonsky, K. S.; McGuinness, O. P.; Kulkarni, R. N. Insulin Signaling in  $\alpha$  Cells Modulates Glucagon Secretion In Vivo. *Cell Metab.* **2009**, *9* (4), 350–361. https://doi.org/10.1016/j.cmet.2009.02.007.

(15) Habegger, K. M.; Heppner, K. M.; Geary, N.; Bartness, T. J.; DiMarchi, R.; Tschöp, M. H. The Metabolic Actions of Glucagon Revisited. *Nat. Rev. Endocrinol.* **2010**, *6* (12), 689–697. https://doi.org/10.1038/nrendo.2010.187.

(16) Dunning, B. E.; Foley, J. E.; Ahrén, B. Alpha Cell Function in Health and Disease: Influence of Glucagon-like Peptide-1. *Diabetologia* **2005**, *48* (9), 1700–1713. https://doi.org/10.1007/s00125-005-1878-0.

(17) Lefebvre, P. J. Glucagon and Adipose Tissue Lipolysis. In *Glucagon I*; Lefèbvre, P. J., Ed.; Handbook of Experimental Pharmacology; Springer: Berlin, Heidelberg, 1983; pp 419–440. https://doi.org/10.1007/978-3-642-68866-9\_19.

(18) Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver-α-Cell Axis | Diabetes
 | American Diabetes
 Association.
 https://diabetesjournals.org/diabetes/article/66/2/235/35269/Glucagon-and-Amino-Acids-Are-Linked in-a-Mutual (accessed 2023-10-26).

(19) Galsgaard, K. D.; Pedersen, J.; Knop, F. K.; Holst, J. J.; Wewer Albrechtsen, N. J. Glucagon Receptor Signaling and Lipid Metabolism. *Front. Physiol.* **2019**, *10*, 1-11.

(20) Holst, J. J.; Holland, W.; Gromada, J.; Lee, Y.; Unger, R. H.; Yan, H.; Sloop, K. W.; Kieffer, T. J.; Damond, N.; Herrera, P. L. Insulin and Glucagon: Partners for Life. *Endocrinology* **2017**, *158* (4), 696–701. https://doi.org/10.1210/en.2016-1748.

(21) Boden, G.; Tappy, L.; Jadali, F.; Hoeldtke, R. D.; Rezvani, I.; Owen, O. E. Role of Glucagon in Disposal of an Amino Acid Load. *Am. J. Physiol.-Endocrinol. Metab.* **1990**, *259* (2), E225–E232. https://doi.org/10.1152/ajpendo.1990.259.2.E225.

(22) Adeva-Andany, M. M.; Funcasta-Calderón, R.; Fernández-Fernández, C.; Castro-Quintela, E.; Carneiro-Freire, N. Metabolic Effects of Glucagon in Humans. *J. Clin. Transl. Endocrinol.* **2019**, *15*, 45–53. https://doi.org/10.1016/j.jcte.2018.12.005.

(23) Friedmann, M. P.; Torbeev, V.; Zelenay, V.; Sobol, A.; Greenwald, J.; Riek, R. Towards Prebiotic Catalytic Amyloids Using High Throughput Screening. *PLOS ONE* **2015**, *10* (12), e0143948. https://doi.org/10.1371/journal.pone.0143948.

(24) Greenwald, J.; Riek, R. On the Possible Amyloid Origin of Protein Folds. *J. Mol. Biol.* **2012**, *421* (4), 417–426. https://doi.org/10.1016/j.jmb.2012.04.015.

(25) Makhlynets, O. V.; Korendovych, I. V. Functional Frankensteins. *Nat. Chem.* **2016**, *8* (9), 823–824. https://doi.org/10.1038/nchem.2603.

(26) Short peptides self-assemble to produce catalytic amyloids | Nature Chemistry. https://www.nature.com/articles/nchem.1894 (accessed 2024-02-27).

(27) Arad, E.; Baruch Leshem, A.; Rapaport, H.; Jelinek, R. β-Amyloid Fibrils Catalyze Neurotransmitter Degradation. *Chem Catal.* **2021**, *1* (4), 908–922. https://doi.org/10.1016/j.checat.2021.07.005.

(28) Arad, E.; Yosefi, G.; Kolusheva, S.; Bitton, R.; Rapaport, H.; Jelinek, R. Native Glucagon Amyloids Catalyze Key Metabolic Reactions. *ACS Nano* **2022**, *16* (8), 12889–12899. https://doi.org/10.1021/acsnano.2c05166.

(29) Arad, E.; Jelinek, R. Catalytic Amyloids. *Trends Chem.* **2022**, *4* (10), 907–917. https://doi.org/10.1016/j.trechm.2022.07.001.

(30) Horvath, I.; Wittung-Stafshede, P. Amyloid Fibers of α-Synuclein Catalyze Chemical Reactions. *ACS Chem. Neurosci.* **2023**, *14* (4), 603–608. https://doi.org/10.1021/acschemneuro.2c00799.

(31) Close, W.; Neumann, M.; Schmidt, A.; Hora, M.; Annamalai, K.; Schmidt, M.; Reif, B.; Schmidt, V.; Grigorieff, N.; Fändrich, M. Physical Basis of Amyloid Fibril Polymorphism. *Nat. Commun.* **2018**, *9* (1), 699. https://doi.org/10.1038/s41467-018-03164-5.

(32)Amyloid structure - one but not the same: the many levels of fibrillar polymorphism - Pedersen -2010-TheFEBSJournal-WileyOnlineLibrary.https://febs.onlinelibrary.wiley.com/doi/full/10.1111/j.1742-4658.2010.07888.x (accessed 2024-02-27).

(33) *Amyloid Polymorphism: Structural Basis and Neurobiological Relevance: Neuron*. https://www.cell.com/neuron/fulltext/S0896-6273(15)00213-

5?\_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0896627315002135%3 Fshowall%3Dtrue (accessed 2024-02-27).

(34) Andersen, C. B.; Hicks, M. R.; Vetri, V.; Vandahl, B.; Rahbek-Nielsen, H.; Thøgersen, H.; Thøgersen,
I. B.; Enghild, J. J.; Serpell, L. C.; Rischel, C.; Otzen, D. E. Glucagon Fibril Polymorphism Reflects Differences in Protofilament Backbone Structure. *J. Mol. Biol.* 2010, 397 (4), 932–946. https://doi.org/10.1016/j.jmb.2010.02.012.

Pedersen, J. S.; Dikov, D.; Flink, J. L; Hjuler, H. A.; Christiansen, G.; Otzen, D. E. The Changing Face of Glucagon Fibrillation: Structural Polymorphism and Conformational Imprinting. *J. Mol. Biol.* 2006, 355 (3), 501–523. https://doi.org/10.1016/j.jmb.2005.09.100.

(36) Adamcik, J.; Mezzenga, R. Amyloid Polymorphism in the Protein Folding and Aggregation Energy Landscape. *Angew. Chem. Int. Ed.* **2018**, *57* (28), 8370–8382. https://doi.org/10.1002/anie.201713416.

(37) Kamerlin, S. C. L.; Warshel, A. The EVB as a Quantitative Tool for Formulating Simulations and Analyzing Biological and Chemical Reactions. *Faraday Discuss.* **2010**, *145* (0), 71–106. https://doi.org/10.1039/B907354J.

(38) Warshel, A.; Weiss, R. M. *An empirical valence bond approach for comparing reactions in solutions and in enzymes*. ACS Publications. https://doi.org/10.1021/ja00540a008.

(39) The empirical valence bond model: theory and applications - Kamerlin - 2011 - WIREsComputationalMolecularScience-WileyOnlineLibrary.https://wires.onlinelibrary.wiley.com/doi/full/10.1002/wcms.10 (accessed 2023-10-26).

(40) Lee, F. S.; Chu, Z. T.; Warshel, A. Microscopic and Semimicroscopic Calculations of Electrostatic Energies in Proteins by the POLARIS and ENZYMIX Programs. *J. Comput. Chem.* **1993**, *14* (2), 161–185. https://doi.org/10.1002/jcc.540140205.

(41) Fuxreiter, M.; Warshel, A. Origin of the Catalytic Power of Acetylcholinesterase: Computer Simulation Studies. *J. Am. Chem. Soc.* **1998**, *120* (1), 183–194. https://doi.org/10.1021/ja972326m.

(42) High-Temperature Equation of State by a Perturbation Method. I. Nonpolar Gases | The Journal of Chemical Physics | AIP Publishing. https://pubs.aip.org/aip/jcp/article-abstract/22/8/1420/203689/High-Temperature-Equation-of-State-by-a?redirectedFrom=fulltext (accessed 2023-10-26).

(43) M. J. Frisch. *Gaussian 16 Revis. A03 Gaussian Inc Wallingford CT* **2016**.

(44) Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. *J. Comput. Chem.* **2009**, *30* (16), 2785–2791. https://doi.org/10.1002/jcc.21256.

(45)Representation of the molecular electrostatic potential by a net atomic charge model - Cox - 1981-JournalofComputationalChemistry-WileyOnlineLibrary.https://onlinelibrary.wiley.com/doi/abs/10.1002/jcc.540020312 (accessed 2023-10-26).---<

(46) Tomasi, J.; Mennucci, B.; Cammi, R. *Quantum Mechanical Continuum Solvation Models - Chemical Reviews (ACS Publications)*. https://pubs.acs.org/doi/abs/10.1021/Cr9904009 (accessed 2018-05-22).

(47) Bayly, C. I.; Cieplak, P.; Cornell, W.; Kollman, P. A. A Well-Behaved Electrostatic Potential Based Method Using Charge Restraints for Deriving Atomic Charges: The RESP Model. *J. Phys. Chem.* **1993**, *97* (40), 10269–10280. https://doi.org/10.1021/j100142a004.

(48) *The Amber biomolecular simulation programs - Case - 2005 - Journal of Computational Chemistry - Wiley Online Library*. https://onlinelibrary.wiley.com/doi/full/10.1002/jcc.20290 (accessed 2023-09-22).

(49) Warshel, A.; Chu, Z. T.; Villa, J.; Strajbl, M.; Schutz, C.; Shurki, A.; Vicatos, S.; Plotnikov, N.; Schopf, P. *Molaris-Xg, Version 9.15*; University of Southern California: Los Angeles, 2012.

(50) Warshel, A.; King, G. Polarization Constraints in Molecular Dynamics Simulation of Aqueous Solutions: The Surface Constraint All Atom Solvent (SCAAS) Model. *Chem. Phys. Lett.* **1985**, *121* (1), 124–129. https://doi.org/10.1016/0009-2614(85)87168-2.

(51) Warshel, A.; Levitt, M. Theoretical Studies of Enzymic Reactions: Dielectric, Electrostatic and Steric Stabilization of the Carbonium Ion in the Reaction of Lysozyme. *J. Mol. Biol.* **1976**, *103* (2), 227–249. https://doi.org/10.1016/0022-2836(76)90311-9.

(52) Russell, S. T.; Warshel, A. Calculations of Electrostatic Energies in Proteins: The Energetics of Ionized Groups in Bovine Pancreatic Trypsin Inhibitor. *J. Mol. Biol.* **1985**, *185* (2), 389–404. https://doi.org/10.1016/0022-2836(85)90411-5.

(53) Lee, F. S.; Warshel, A. A Local Reaction Field Method for Fast Evaluation of Long-range Electrostatic Interactions in Molecular Simulations. *J. Chem. Phys.* **1992**, *97* (5), 3100–3107. https://doi.org/10.1063/1.462997. (54) Simulation of free energy relationships and dynamics of SN2 reactions in aqueous solution | Journal of the American Chemical Society. https://pubs.acs.org/doi/pdf/10.1021/ja00224a011 (accessed 2023-10-26).

(55) Singh, N.; Warshel, A. Absolute Binding Free Energy Calculations: On the Accuracy of Computational Scoring of Protein–Ligand Interactions. *Proteins Struct. Funct. Bioinforma.* **2010**, *78* (7), 1705–1723. https://doi.org/10.1002/prot.22687.

(56) Sham, Y. Y.; Chu, Z. T.; Tao, H.; Warshel, A. Examining methods for calculations of binding free energies: LRA, LIE, PDLD-LRA, and PDLD/S-LRA calculations of ligands binding to an HIV protease. *Proteins Struct. Funct. Bioinforma.* **2000**, *39* (4), 393–407. https://doi.org/10.1002/(SICI)1097-0134(20000601)39:4<393::AID-PROT120>3.0.CO;2-H.

(57) Lee, F. S.; Chu, Z.-T.; Bolger, M. B.; Warshel, A. Calculations of Antibody-Antigen Interactions: Microscopic and Semi-Microscopic Evaluation of the Free Energies of Binding of Phosphorylcholine Analogs to McPC603. *Protein Eng. Des. Sel.* **1992**, *5* (3), 215–228. https://doi.org/10.1093/protein/5.3.215.

(58) Muegge, I.; Tao, H.; Warshel, A. A Fast Estimate of Electrostatic Group Contributions to the Free Energy of Protein-Inhibitor Binding. *Protein Eng. Des. Sel.* **1997**, *10* (12), 1363–1372. https://doi.org/10.1093/protein/10.12.1363.

(59) Warshel, A.; Sharma, P. K.; Kato, M.; Parson, W. W. Modeling Electrostatic Effects in Proteins. *Biochim. Biophys. Acta BBA - Proteins Proteomics* **2006**, *1764* (11), 1647–1676. https://doi.org/10.1016/j.bbapap.2006.08.007.

(60) Schutz, C. N.; Warshel, A. What Are the Dielectric "Constants" of Proteins and How to Validate Electrostatic Models? *Proteins Struct. Funct. Bioinforma.* **2001**, *44* (4), 400–417. https://doi.org/10.1002/prot.1106.

(61) Asadi, M.; Warshel, A. Analyzing the Reaction of Orotidine 5'-Phosphate Decarboxylase as a Way to Examine Some Key Catalytic Proposals. *J. Am. Chem. Soc.* **2023**, *145* (2), 1334–1341. https://doi.org/10.1021/jacs.2c11728.